Literature DB >> 18247378

Interferon-inducible protein IFIXalpha inhibits cell invasion by upregulating the metastasis suppressor maspin.

Hirohito Yamaguchi1, Yi Ding, Jin-Fong Lee, Ming Zhang, Ashutosh Pal, William Bornmann, Duen-Hwa Yan, Mien-Chie Hung.   

Abstract

IFIXalpha, a member of the interferon-inducible HIN-200 family, has been identified as a putative tumor suppressor. However, the molecular mechanisms underlying IFIXalpha-mediated tumor suppression are poorly understood. In the present study, we demonstrated that the metastasis suppressor maspin acts as the downstream target of IFIXalpha. IFIXalpha suppressed the invasion activity of MDA-MB-468 breast cancer cells, and its inhibitory effect was reversed by the knockdown of maspin. Both Maspin mRNA and protein were upregulated by IFIXalpha. Histone deacetylase (HDAC) inhibitors, but not DNA methyltransferase inhibitor upregulated maspin, and HDAC1 inhibited the transactivation of maspin promoter. Although the HDAC1 protein was downregulated in IFIXalpha-expressing cells, IFIXalpha did not affect HDAC1 mRNA levels. Conversely, a proteasome inhibitor restored the level of HDAC1 protein in IFIXalpha-expressing cells, and the polyubiqutination of HDAC1 was promoted by IFIXalpha, suggesting that HDAC1 is regulated by IFIXalpha through a ubiquitin-proteasome pathway. Together, these data provide novel insights into the tumor-suppressive function of IFIXalpha.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18247378      PMCID: PMC2596649          DOI: 10.1002/mc.20423

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  20 in total

1.  Epigenetic silencing of maspin gene expression in human breast cancers.

Authors:  F E Domann; J C Rice; M J Hendrix; B W Futscher
Journal:  Int J Cancer       Date:  2000-03-15       Impact factor: 7.396

Review 2.  Histone deacetylases and cancer: causes and therapies.

Authors:  P Marks; R A Rifkind; V M Richon; R Breslow; T Miller; W K Kelly
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

Review 3.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

Authors:  Paul A Marks; Ronald Breslow
Journal:  Nat Biotechnol       Date:  2007-01       Impact factor: 54.908

4.  Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model.

Authors:  H Y Shi; W Zhang; R Liang; S Abraham; F S Kittrell; D Medina; M Zhang
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

Review 5.  Maspin: the new frontier.

Authors:  Zhila Khalkhali-Ellis
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

6.  Role for histone deacetylase 1 in human tumor cell proliferation.

Authors:  Silvia Senese; Katrin Zaragoza; Simone Minardi; Ivan Muradore; Simona Ronzoni; Alfonso Passafaro; Loris Bernard; Giulio F Draetta; Myriam Alcalay; Christian Seiser; Susanna Chiocca
Journal:  Mol Cell Biol       Date:  2007-04-30       Impact factor: 4.272

7.  Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer.

Authors:  Nicolai Maass; Marco Biallek; Frank Rösel; Christian Schem; Nobuyuki Ohike; Ming Zhang; Walter Jonat; Koichi Nagasaki
Journal:  Biochem Biophys Res Commun       Date:  2002-09-13       Impact factor: 3.575

8.  Tamoxifen induces the expression of maspin through estrogen receptor-alpha.

Authors:  Zesheng Liu; Heidi Y Shi; Zafar Nawaz; Ming Zhang
Journal:  Cancer Lett       Date:  2004-06-08       Impact factor: 8.679

9.  Antitumor activity of IFIX, a novel interferon-inducible HIN-200 gene, in breast cancer.

Authors:  Yi Ding; Li Wang; Li-Kuo Su; Jennifer A Frey; Ruping Shao; Kelly K Hunt; Duen-Hwa Yan
Journal:  Oncogene       Date:  2004-06-03       Impact factor: 9.867

Review 10.  Histone deacetylase inhibitors: molecular mechanisms of action.

Authors:  W S Xu; R B Parmigiani; P A Marks
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

View more
  7 in total

1.  HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.

Authors:  Xiaohua Li; Alexander Kaplun; Fulvio Lonardo; Elisabeth Heath; Fazlul H Sarkar; Jonathan Irish; Wael Sakr; Shijie Sheng
Journal:  Mol Cancer Res       Date:  2011-05-26       Impact factor: 5.852

Review 2.  Functions and roles of IFIX, a member of the human HIN-200 family, in human diseases.

Authors:  Shan Wang; Jie Bai
Journal:  Mol Cell Biochem       Date:  2022-01-18       Impact factor: 3.396

3.  "Stealth dissemination" of macrophage-tumor cell fusions cultured from blood of patients with pancreatic ductal adenocarcinoma.

Authors:  Gary A Clawson; Gail L Matters; Ping Xin; Christopher McGovern; Eric Wafula; Claude dePamphilis; Morgan Meckley; Joyce Wong; Luke Stewart; Christopher D'Jamoos; Naomi Altman; Yuka Imamura Kawasawa; Zhen Du; Loren Honaas; Thomas Abraham
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

4.  PYHIN1 regulates pro-inflammatory cytokine induction rather than innate immune DNA sensing in airway epithelial cells.

Authors:  Davide Massa; Marcin Baran; Jose A Bengoechea; Andrew G Bowie
Journal:  J Biol Chem       Date:  2020-02-26       Impact factor: 5.157

5.  PYHIN1 correlates with CD8+ T cells infiltration and confers good patient survival in oral cancer.

Authors:  Jian-Ming Ding; Wen-Rong Lin; Zhao-Dong Fei; Chuan-Ben Chen
Journal:  J Dent Sci       Date:  2021-07-08       Impact factor: 2.080

6.  Interferon-inducible protein, IFIX, has tumor-suppressive effects in oral squamous cell carcinoma.

Authors:  Shan Wang; Fang Li; Haixia Fan
Journal:  Sci Rep       Date:  2021-10-01       Impact factor: 4.379

7.  Maspin is a PTEN-Upregulated and p53-Upregulated Tumor Suppressor Gene and Acts as an HDAC1 Inhibitor in Human Bladder Cancer.

Authors:  Yu-Hsiang Lin; Ke-Hung Tsui; Kang-Shuo Chang; Chen-Pang Hou; Tsui-Hsia Feng; Horng-Heng Juang
Journal:  Cancers (Basel)       Date:  2019-12-18       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.